When depression remains difficult to manage despite trying antidepressants, or symptoms continue to interfere with work, relationships, and daily responsibilities, a person may want to discuss additional treatment options with a mental health professional. In-person care in Maryland may include evaluation for SPRAVATO® (esketamine), a prescription nasal spray used for specific depression indications under medical supervision. It may be considered for adults with treatment-resistant depression, and for depressive symptoms associated with major depressive disorder with acute suicidal ideation or behavior; use for PTSD is not an FDA-approved indication.
How It Works
Treatment involves a prescribed nasal spray and required supervision in a qualified healthcare setting:
- Nasal Administration: The patient self-administers the prescribed spray under healthcare professional supervision.
- Observation After Dosing: The patient remains at the treatment location for monitoring because temporary effects such as sedation, dizziness, dissociation, and increased blood pressure may occur.
- Treatment Alongside Other Care: Depending on the indication, SPRAVATO may be used with an oral antidepressant and as part of a broader depression treatment plan.
- Response Monitoring: The treating professional reviews response and tolerability to help determine whether treatment should continue.
Potential Benefits and Important Considerations
For some adults with treatment-resistant depression, SPRAVATO may help reduce depressive symptoms when used as prescribed. Response varies, and treatment does not guarantee improvement or replace the need for ongoing clinical care. A healthcare professional should explain the expected benefits, risks, medication requirements, and monitoring arrangements before treatment begins.
What to Expect
SPRAVATO is administered in person, and patients should plan to remain at the clinic for the required observation period after each dose. For treatment-resistant depression, the labeled schedule is generally twice weekly for the first four weeks, followed by weekly treatment during weeks five through eight, with later frequency individualized according to response; other indications may have different treatment instructions. Patients must arrange transportation home and should not drive or operate machinery until the next day after a restful night’s sleep, as directed in the prescribing information.
Get Support in Understanding Your Concerns
If attention, memory, or learning difficulties have been affecting your daily routine, reach out. to discuss what you’ve been experiencing. You can ask questions, understand your assessment options, and decide what feels like the appropriate next step.

